Prometheus     |     PredictrPK IFX    LinkedIn  twitter

How do evidence based treatment plans impact patient lives?

If Olivia were in your care, what treatment ​​​​​​modifications would you consider?

(Check all that apply)

Clinical Scenario:

  • Approximately 3 weeks before her next scheduled IFX infusion, Olivia reports diffuse abdominal pain, nausea, diarrhea and general fatigue.
  • PredictrPK is ordered to assess current serum IFX, estimated 8-week IFX trough level, and antibodies to IFX (ATI).

Results Interpretation:

  • Results indicate a serum IFX concentration of 8.0 µg/mL at the time of sample collection and an ATI of 6.4 U/mL.
  • The PredictrPK algorithm estimates 8-week trough IFX concentrations will be approximately 4 µg/mL.
  • An alternative dose and interval table, unique to Olivia and her pharmacokinetic profile, estimate how treatment modifications may impact Olivia's next trough level.

PredictrPK IFX was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) laboratory guidelines, and is performed exclusively in our high complexity CLIA certified and College of American Pathologists (CAP) accredited clinical laboratory. As a laboratory developed test, it has not been cleared or approved by the US FDA. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.

Copyright © 2022 Prometheus Laboratories. All rights reserved